On Sept. 14, 2020, Pascal Biosciences and SoRSE Technology announced they had entered into a collaborative research agreement to advance Pascal’s PAS-393 into clinical testing.

Pascal and SoRSE will share their respective technologies to test the cannabinoid PAS-393 in human volunteers, enabling testing of cancer patients treated with checkpoint inhibitors.